leisure time -WSS

leisure time

author：fashion 2025-09-27 19:37:33 - browse：245

A new asthma treatment that could be administered just once every six months has succeeded in two Phase 3 trials, developer GlaxoSmithKline announced Tuesday.

The drug, depemokimab, is designed to treat asthma by targeting a protein called interleukin-5, or IL-5. The protein is linked to the type of inflammation found in most severe asthma cases, according to the pharma company.

Depemokimab hit its primary endpoints in the trials, reducing asthma attacks over a year’s time frame. The company didn’t disclose exact details from the SWIFT-1 and SWIFT-2 trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Device maker Teleflex to acquire urology company for $600M

WSS

Emergency medicine has repudiated 'excited delirium.' Now what?

Dems pitch expanding Medicare power to negotiate drug prices

How doctors’ personal politics affect patients

FDA has safety concerns on CRISPR

Hospitals warn Medicare's drug payment fix is ‘unlawful’

The pink breast cancer awareness ribbon needs a redesign

knowledge

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Truvian presents data for its desktop blood

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

The FDA weighs the risks of candy

What does generative AI mean for health care? We asked experts

Senate panel puts off hardest PBM reforms for another day

At least 13 dead in Texas as scorching temps continue

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Bright Health sells Medicare Advantage business to Molina

Biden's order seeks to regulate AI risk without stifling innovation

hotspot

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Testing for cancer recurrence creates a new limbo for patients

Chimpanzees, like humans and whales, get menopause: Study

Physician subsidies by hospitals soar in wake of No Surprises Act

Testing for cancer recurrence creates a new limbo for patients

Cassava reveals details — and problems — with Alzheimer's study

leisure time

focus

leisure time

focus